Skip to main content
SpringerLink
Log in

Research at the interface of industry, academia and regulatory science

  • Foreword
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Borchers, A.T., Hagie, F., Keen, C.L. & Gershwin, M.E. Clin. Ther. 29, 1–16 (2007).

    Article  Google Scholar 

  2. Miller, S.A. J. Nutr. 123, 279–284 (1993).

    Article  CAS  Google Scholar 

  3. Collins, J.M. Chem. Biol. Interact. 134, 237–242 (2001).

    Article  CAS  Google Scholar 

  4. Peters, T.S. Toxicol. Pathol. 33, 146–154 (2005).

    Article  CAS  Google Scholar 

  5. Voisin, E.M., Ruthsatz, M., Collins, J.M. & Hoyle, P.C. Regul. Toxicol. Pharmacol. 12, 107–116 (1990).

    Article  CAS  Google Scholar 

  6. Jacobs, A. & Jacobson-Kram, D. Toxicol. Sci. 81, 260–262 (2004).

    Article  CAS  Google Scholar 

  7. Jacobson-Kram, D. & Contrera, J.F. Toxicol. Sci. 96, 16–20 (2007).

    Article  CAS  Google Scholar 

  8. Miller, M.A. Int. J. Toxicol. 20, 149–152 (2001).

    Article  CAS  Google Scholar 

  9. MacGregor, J.T. Toxicol. Sci. 75, 236–248 (2003).

    Article  CAS  Google Scholar 

  10. Tong, W. et al. Environ. Health Perspect. 111, 1819–1826 (2003).

    Article  CAS  Google Scholar 

  11. Gutman, S. & Kessler, L.G. Nat. Rev. Cancer 6, 565–571 (2006).

    Article  CAS  Google Scholar 

  12. Lesko, L.J. Clin. Pharmacol. Ther. 81, 807–816 (2007).

    Article  CAS  Google Scholar 

  13. Anonymous. Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (FDA, Washington, DC, 2004; accessed 23 April 2010). http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm

  14. Woosley, R.L. & Cossman, J. Clin. Pharmacol. Ther. 81, 129–133 (2007).

    Article  CAS  Google Scholar 

  15. Anonymous. US Food and Drug Administration. Critical Path Opportunities List - March 2006 (FDA, Washington, DC, 2006; accessed 23 April 2010). http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077258.pdf

  16. Irwin, D.A. & Klenow, P.J. Proc. Natl. Acad. Sci. USA 93, 12739–12742 (1996).

    Article  CAS  Google Scholar 

  17. The Food and Drug Adminstration. Fed. Regist. 70, 74823–74826 (2005).

  18. Marrer, E. & Dieterle, F. Chem. Biol. Drug Des. 69, 381–394 (2007).

    Article  CAS  Google Scholar 

  19. Mattes, W.B. Methods Mol. Biol. 460, 221–238 (2008).

    Article  Google Scholar 

  20. Kim, W.R., Flamm, S.L., Di Bisceglie, A.M. & Bodenheimer, H.C. Hepatology 47, 1363–1370 (2008).

    Article  CAS  Google Scholar 

  21. Zweig, M.H. & Campbell, G. Clin. Chem. 39, 561–577 (1993).

    CAS  PubMed  Google Scholar 

  22. Senior, J.R. Clin. Liver Dis. 11, 507–524 (2007).

    Article  Google Scholar 

  23. The Food and Drug Adminstration. Fed. Regist. 72, 60681–60682 (2007).

  24. Wagner, J.A., Williams, S.A. & Webster, C.J. Clin. Pharmacol. Ther. 81, 104–107 (2007).

    Article  CAS  Google Scholar 

  25. Lee, J.W. et al. Pharm. Res. 23, 312–328 (2006).

    Article  CAS  Google Scholar 

  26. Wagner, J.A. Annu. Rev. Pharmacol. Toxicol. 48, 631–651 (2008).

    Article  CAS  Google Scholar 

  27. Goodsaid, F.M., Frueh, F.W. & Mattes, W. Toxicology 245, 219–223 (2008).

    Article  CAS  Google Scholar 

  28. Schetz, M., Dasta, J., Goldstein, S. & Golper, T. Curr. Opin. Crit. Care 11, 555–565 (2005).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Critical Path Institute, Tucson, Arizona, USA

    William B Mattes, Elizabeth Gribble Walker & Raymond L Woosley

  2. European Medicines Agency, Canary Wharf, London, UK

    Eric Abadie

  3. Department of Laboratory Sciences and Investigative Toxicology, Safety Assessment, Merck Research Laboratories, West Point, Pennsylvania, USA

    Frank D Sistare

  4. Novartis, San Diego, California, USA

    Jacky Vonderscher

  5. Food and Drug Administration, Silver Spring, Maryland, USA

    Janet Woodcock

Authors
  1. William B Mattes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth Gribble Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric Abadie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frank D Sistare
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacky Vonderscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Janet Woodcock
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Raymond L Woosley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William B Mattes.

Ethics declarations

Competing interests

F.D.S. is an employee of Merck and J.V. is an employee of Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mattes, W., Walker, E., Abadie, E. et al. Research at the interface of industry, academia and regulatory science. Nat Biotechnol 28, 432–433 (2010). https://doi.org/10.1038/nbt0510-432

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0510-432

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation